Cargando…

Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists

BACKGROUND: Observational data may inform novel drug development programs by identifying previously unappreciated, clinical benefits of existing drugs. Several preclinical and clinical studies have suggested emergent therapeutic utility of drugs acting on the N-methyl-d-aspartate (NMDA) receptor, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kern, David M., Cepeda, M. Soledad, Flores, Christopher M., Wittenberg, Gayle M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907035/ https://www.ncbi.nlm.nih.gov/pubmed/33537916 http://dx.doi.org/10.1007/s40263-020-00789-3

Ejemplares similares

Revealing Unknown Benefits of Existing Medications to Aid the Discovery of New Treatments for Post‐Traumatic Stress Disorder
por: Kern, David M., et al.
Publicado: (2021)

Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
por: Kikuchi, Tetsuro
Publicado: (2020)

Effects of Memantine, an NMDA Antagonist, on Metabolic Syndromes in Female NMRI Mice
por: Osanloo, Naser, et al.
Publicado: (2015)

The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi
por: Santos Souza, Higo Fernando, et al.
Publicado: (2019)

Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications
por: Kern, David M., et al.
Publicado: (2019)

Computational Modeling of Therapy with the NMDA Antagonist in Neurodegenerative Disease: Information Theory in the Mechanism of Action of Memantine
por: Świetlik, Dariusz, et al.
Publicado: (2022)

Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer’s Disease, In Silico Trials
por: Świetlik, Dariusz, et al.
Publicado: (2022)

The effect of the NMDA channel blocker memantine on salicylate-induced tinnitus in rats
por: RALLI, M., et al.
Publicado: (2014)

Memantine, an Antagonist of the NMDA Glutamate Receptor, Affects Cell Proliferation, Differentiation and the Intracellular Cycle and Induces Apoptosis in Trypanosoma cruzi
por: Damasceno, Flávia Silva, et al.
Publicado: (2014)

Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine
por: Pringle, A, et al.
Publicado: (2012)

Comprehensive Real-World Assessment of Marketed Medications to Guide Parkinson’s Drug Discovery
por: Cepeda, M. Soledad, et al.
Publicado: (2019)

Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity
por: Lopes, João P, et al.
Publicado: (2013)

Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease
por: Takahashi, Hiroto, et al.
Publicado: (2015)

The NMDA antagonist memantine affects training induced motor cortex plasticity – a study using transcranial magnetic stimulation [ISRCTN65784760]
por: Schwenkreis, Peter, et al.
Publicado: (2005)

Corrigendum: Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease
por: Takahashi, Hiroto, et al.
Publicado: (2016)

Autism: Comorbidities and Treatment Patterns in the Real World, a Retrospective Cohort Study Among Children, Adolescents and Adults Newly Diagnosed with Autism
por: Shoaib, Azza, et al.
Publicado: (2021)

Treatment patterns of patients diagnosed with major depressive disorder and suicidal ideation or attempt: a U.S. population-based study utilizing real-world data
por: Kern, David M., et al.
Publicado: (2021)

Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult
por: Ferrer-Acosta, Yancy, et al.
Publicado: (2022)

The Effect of an α-7 Nicotinic Allosteric Modulator PNU120596 and NMDA Receptor Antagonist Memantine on Depressive-like Behavior Induced by LPS in Mice: The Involvement of Brain Microglia †
por: Alzarea, Sami, et al.
Publicado: (2022)

Altered Actions of Memantine and NMDA-Induced Currents in a New Grid2-Deleted Mouse Line
por: Kumagai, Ayako, et al.
Publicado: (2014)

Disrupting D1-NMDA or D2-NMDA receptor heteromerization prevents cocaine’s rewarding effects but preserves natural reward processing
por: Andrianarivelo, Andry, et al.
Publicado: (2021)

NMDA Receptor Antagonists for Treatment of Depression
por: Ates-Alagoz, Zeynep, et al.
Publicado: (2013)

Memantine protects thalamocortical hyper‐glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc(−)
por: Okada, Motohiro, et al.
Publicado: (2019)

Memantine increases NMDA receptor level in the prefrontal cortex but fails to reverse apomorphine-induced conditioned place preference in rats
por: Ndlazi, Ziphozethu, et al.
Publicado: (2018)

Allosteric antagonist action at triheteromeric NMDA receptors
por: Gibb, Alasdair J.
Publicado: (2022)

Recovery of NMDA receptor currents from MK-801 blockade is accelerated by Mg(2+) and memantine under conditions of agonist exposure
por: McKay, Sean, et al.
Publicado: (2013)

A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients
por: Bent-Ennakhil, Nawal, et al.
Publicado: (2017)

Natural Reward Experience Alters AMPA and NMDA Receptor Distribution and Function in the Nucleus Accumbens
por: Pitchers, Kyle K., et al.
Publicado: (2012)

Behavioral Consequences of NMDA Antagonist-Induced Neuroapoptosis in the Infant Mouse Brain
por: Yuede, Carla M., et al.
Publicado: (2010)

Real-world data analysis of patients with cancer of unknown primary
por: Kang, Sora, et al.
Publicado: (2021)

Pharmacodynamics of Memantine: An Update
por: Rammes, G, et al.
Publicado: (2008)

NMDA receptor-dependent plasticity in the nucleus accumbens connects reward-predictive cues to approach responses
por: Vega-Villar, Mercedes, et al.
Publicado: (2019)

NMDA Receptor Antagonist Ketamine Impairs Feature Integration in Visual Perception
por: Meuwese, Julia D. I., et al.
Publicado: (2013)

Ventral Midbrain NMDA Receptor Blockade: From Enhanced Reward and Dopamine Inactivation
por: Hernandez, Giovanni, et al.
Publicado: (2016)

Modulation of Functional EEG Networks by the NMDA Antagonist Nitrous Oxide
por: Kuhlmann, Levin, et al.
Publicado: (2013)

NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
por: Vanle, Brigitte, et al.
Publicado: (2018)

Promises and Pitfalls of NMDA Receptor Antagonists in Treating Violent Aggression
por: Bartsch, Caitlyn J., et al.
Publicado: (2022)

Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists
por: Pereira, Nuno A. L., et al.
Publicado: (2016)

NMDA Receptor Antagonists Increase the Release of GLP-1 From Gut Endocrine Cells
por: Cyranka, Malgorzata, et al.
Publicado: (2022)

Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities
por: Torres, Eva, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dsd52sst5rdndjjl2q7u74h9tt